Abstract
Enterocytozoon bieneusi microsporidiosis is an emerging disease in immunocompromised patients. We report 2 cases of this disease in allogeneic hematopoietic stem cell transplant patients successfully treated with fumagillin. Thrombocytopenia occurred but without major adverse events. Modifications of immunosuppression could be avoided when E. bieneusi is rapidly identified and fumagillin therapy is started promptly.
Keywords:
Enterocytozoon bieneusi; allogeneic; antiprotozoal drugs; fumagillin; hematopoietic stem cell transplant recipients; immunocompromised patients; microsporidia; microsporidiosis; obligate intracellular parasite; parasites; protozoa; transplantation.
MeSH terms
-
Adult
-
Antifungal Agents / administration & dosage*
-
Antifungal Agents / adverse effects
-
Cyclohexanes / administration & dosage*
-
Cyclohexanes / adverse effects
-
Enterocytozoon / drug effects*
-
Enterocytozoon / pathogenicity
-
Enterocytozoon / physiology
-
Fatty Acids, Unsaturated / administration & dosage*
-
Fatty Acids, Unsaturated / adverse effects
-
Female
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Immunosuppressive Agents / therapeutic use
-
Leukemia, Myeloid / immunology*
-
Leukemia, Myeloid / pathology
-
Leukemia, Myeloid / therapy
-
Male
-
Microsporidiosis / diagnosis
-
Microsporidiosis / drug therapy*
-
Microsporidiosis / microbiology
-
Middle Aged
-
Mycophenolic Acid / therapeutic use
-
Platelet Count
-
Prednisone / therapeutic use
-
Sesquiterpenes / administration & dosage
-
Sesquiterpenes / adverse effects
-
Thrombocytopenia / chemically induced
-
Treatment Outcome
Substances
-
Antifungal Agents
-
Cyclohexanes
-
Fatty Acids, Unsaturated
-
Immunosuppressive Agents
-
Sesquiterpenes
-
fumagillin
-
Mycophenolic Acid
-
Prednisone